Immunity, B cells & regulatory B cell responses during inflammation (autoimmune/infection) {#S0001}
==========================================================================================

Immunological studies have shown that successful clearance of any invading pathogen depends on effective balance between immune cells and their secreted products such as cytokines, antibodies and chemokines. Depending on the nature of infection, immune cell balance can be altered through biological processes such as necrosis, pyroptosis, programmed cell death and apoptosis \[[@B1]\]. These cellular processes are triggered mostly by intracellular pathogens such as *Mycobacterium tuberculosis*, which has evolved to suppress immune responses by effector T cells through release of bacterial vesicles that expresses lipoarabinomannan and other lipoglycans \[[@B2]\]. These bacteria suppress immune activation through recruitment of mesenchymal stem cells, which secrete immunosuppressive cytokines and nitric oxide \[[@B3]\].

Even though the Bacillus Calmette-Guerin (BCG) vaccination has been in use for years as it stimulates the immune system and shortens the specific antibody response against *M. tuberculosis* infection, which targets lipoarabinomannan embedded on their cell wall \[[@B4]\], there is still a need for advances that will better eradiate or control the infection. These antibodies are secreted by a subpopulation of B cells (plasma cells). Furthermore, they facilitate rapid cell-mediated immunity through pathogen opsonization and binding of their Fcγ receptors (FcγR) with professional antigen-presenting cells (APC) that result in internalization of the pathogen \[[@B5]\]. However, *M. tuberculosis* is known to reside and multiply within these antigen-presenting cells, leading to formation of granuloma structures \[[@B6],[@B7]\]. Dissemination of these structures and progression to active tuberculosis has been shown to affect the frequency of immunological cells such as circulating peripheral B cells \[[@B8],[@B9]\]. The tuberculosis (TB) pathogen takes advantage of this imbalance in the immune system and multiplies further, thus infecting more and more cells.

Immune system inadequacy or manipulation by *M. tuberculosis* has highlighted the importance of exploring other functions played by immune cell subtypes as a means to better control infection. It has become evident through research that regulatory functions in different immunological cells, including B cells, play more than just a role of suppressing aggressive immune responses during autoimmune and infectious diseases. These regulatory subsets play a major role in balancing the immune system and better facilitate elimination and control of pathogens and resolution of inflammation \[[@B10]\]. Immune suppression functions are mediated by a group of specialized regulatory cells in the innate (myeloid-derived suppressor cells and natural killer cells) \[[@B14],[@B15]\] and adaptive arms, mainly of the T (regulatory T cells \[Tregs\]) and B lymphocytes (regulatory B-lymphocytes \[Bregs\]) \[[@B10],[@B16]\], which express differential surface receptors and secrete a range of cytokine profiles.

Development of Bregs and other B cell subtypes with different immune function ([Figure 1](#F0001){ref-type="fig"}) is enhanced by various factors including activated/stimulated cellular pathway, type of stimulant and extracellular concentration of micronutrients \[[@B11]\]. In particular, regulatory function in B cells was first described in experimental autoimmune encephalomyelitis \[[@B17]\]. It was initially thought that the primary function of these Bregs was to maintain the immune environment until Tregs are matured enough to take over the role, as the functions mediated by these cell types (as described by \[[@B18]) show them to be alternating, with Bregs regulating early inflammation during experimental autoimmune encephalomyelitis while regulatory T cell frequencies increase toward the late phase of inflammation.

![**Different B cell functional response to inflammation.**\
Stimulation of any of the B cell functions depend on the nature of the pathogenic material, whereas memory B cells are long lasting immunological memory cells that bear specific receptors from previous infection.](fsoa-05-379-g1){#F0001}

As depicted in [Figure 1](#F0001){ref-type="fig"} and [Figure 2](#F0002){ref-type="fig"}, these cells exert their effect through secretion of soluble proteins (blocking specific intracellular pathways) and expression of surface ligand molecules such as Fas-L, FoxP3 and programmed death ligand \[[@B10],[@B18]\], which enhance interaction with cells bearing receptors for those specific ligands and induce apoptosis or programmed death.

![**Biological pathways involved in development of regulatory B cells by various extracellular antigens have not yet been characterized and need further investigations.**](fsoa-05-379-g2){#F0002}

Regulatory B cells have been implicated in many inflammatory studies including allograft tolerance, cancer, autoimmune diseases and infection \[[@B9],[@B19],[@B20]\], where they have been shown to inhibit function and proliferation of T helper 1 and T helper 17 cells \[[@B21]\]. During autoimmune diseases, these cells increase tolerance of selfantigens, thus preventing destruction of the body\'s own cells. Similarly, during infection and inflammatory responses, they limit aggressiveness of the immune system and prevent persisting immune responses after clearance of the pathogen. Even though Bregs have not been extensively studied during TB disease, current evidence suggests that B cells with anti-inflammatory properties are present in smaller numbers in the peripheral stream and these decrease drastically during chronic infectious diseases \[[@B23]\]. These cells are displayed at higher frequencies in healthy individuals and disappear over time during chronic immune responses, thus leading to immune system imbalance \[[@B8],[@B20],[@B25]\]. Bregs are continuously reported to be dysfunctional during inflammation; furthermore, this is thought to be associated with exacerbation of disease state, especially in autoimmune diseases \[[@B26]\].

Various antigens are known to drive development of Bregs through upregulation of IL-10 secretion. These include BiP, BCG, LPS, infectious agents and TLR-9a \[[@B27]\]. In particular, BiP has been shown to resolve inflammation in rheumatoid arthritis by upregulating anti-inflammatory cytokine production by immune cells \[[@B30],[@B31]\]. However, as depicted in [Figure 2](#F0002){ref-type="fig"}, the biological pathways involved in the development of these cells by different antigens including BiP remains unknown.

Additionally, functional and phenotypic characterization of these cells is still expanding in the context of different inflammatory conditions and new makers are still being identified that relate to extracellular environment composition during their development. It has been shown by recent studies that apart from IL-10 secretion, these cells are capable of secreting other soluble molecules including sFas-L, TGF-b, granzyme-B and IL-35, which play crucial roles in suppressing inflammation \[[@B10],[@B29],[@B32]\].

Phenotypically identified subsets of regulatory B cells during inflammation {#S0002}
---------------------------------------------------------------------------

Identification of Bregs is based on both extracellular surface immunoglobulin expression and cytokine profiles, merely because these properties determine the mode of regulation by these cell types. As postulated in [Figure 3](#F0003){ref-type="fig"} there are four common categories of Bregs and these include IL-10-producing Bregs (commonly known as B*10* cells) that produce IL-10 as major cytokine \[[@B33]\], transforming growth factor-β-producing B cells (B-*TGF-β*) and FoxP3-expressing B cells (B-*FoxP3*) \[[@B10]\]. Additionally, IL-35 is another cytokine secreted by regulatory B cells, either alone or in conjunction with IL-10, to modulate immune responses during inflammation \[[@B34]\]. Several phenotypes have been identified based on extracellular surface immunoglobulin expression within each Bregs category in various studies of both humans and mice.

![**Circulating CD19^+^ B cells have the potential to develop to regulatory B cells with different regulatory markers depending on their stage of development.**\
The regulatory trait has been identified within B1 cells, marginal zone B cells and transitional-2 marginal zone B cells.](fsoa-05-379-g3){#F0003}

In humans, the majority of B10 cells are represented by expression of CD19^+^CD24^hi^CD38^hi^, CD1d^hi^CD5^+^, CD19^+^TIM1^+^ on their surface \[[@B9],[@B23],[@B33],[@B35]\]. Similarly, Shen *et al*., (2014) described a subpopulation of IL-35-producing Bregs differentiating from plasma cells expressing the phenotype IgM^+^CD138^hi^TACI^+^CRCX^+^CD1d^+^Tim1^int^ in mice \[[@B34]\]. However, IL-21 has been shown to drive regulatory function in B cells by upregulating expression of granzyme-B in conjunction with IL-10. This subset has been phenotypically identified as CD19^+^CD38^+^CD147^+^CD1d^+^IgM^+^ \[[@B36]\]. Contradicting results in relation to IL-10 were observed in an HIV study whereby GraB^+^ Bregs did not produce IL-10 \[[@B36],[@B37]\]. B cell regulatory function linked with FasL and PD-L1 expression has been described in both inflammatory and healthy state in humans; these appear in varying frequencies in relation to the inflammatory state and were reported to be higher in healthy than in infected individuals \[[@B25],[@B29]\]. CD19^+^FasL^+^ and CD19^+^PD-L1^+^ regulatory subsets secrete IL-10, although IL-10 biosynthesis intracellular pathways are not fully exploited by these B cell subpopulations \[[@B25],[@B38]\].

However, there has been reports that a significant amount of IL-10 production by B cells occurs through involvement of toll-like receptor (TLR) molecules rather than B cell receptors or CD40 involvement \[[@B39]\]. CD1d^hi^CD5^+^ B cells were reported to be inducible for IL-10 secretion in significant amounts through TLR-9 using LPS and intracellularly mediated by MyD88/STAT3 pathway \[[@B13],[@B33],[@B39]\]. FoxP3-expressing B cells in healthy human blood samples were first described in a study by Noh *et al*., (2010) within the CD19^+^CD5^+^ population \[[@B40]\]. These cells appeared in higher frequencies within the CD5^+^ group than in the CD5^-^ group, and they also showed increased apoptotic characteristics than other B cell groups. A subsequent study by Guo *et al*., (2015) described FoxP3-expressing CD19^+^ B cells to be of greater frequencies in healthy individuals than in patients with rheumatoid arthritis (RA) \[[@B10]\].

Although further studies still need to be done on FoxP3^+^ B cells, Guo *et al*., (2015) also compared their frequency with TGF-β CD19^+^ B cells and found no significant difference among the expression frequencies of these groups in both healthy and RA groups \[[@B10]\]. Regulatory function and frequency in B cells and other immune cells is affected by varying antigens in the cellular environment.

BiP affects immune cell function {#S0003}
--------------------------------

The BiP is a 78 kDa heat shock protein naturally occurring in the lumen of the endoplasmic reticulum (ER) and aids in proper peptide folding \[[@B41]\]. Synthesis and expression of this protein has been reported to be upregulated during cellular stress that might be due to glucose starvation or in response to accumulation of unfolded proteins within the cell \[[@B42],[@B43]\]. Its activation/synthesis was initially observed in a study by Munro and Pelham, (1986) where BiP was shown to be expressed in high concentrations in antibody-producing B cells due to high levels of synthesized immunoglobulin inhabiting endoplasmic reticulum than in resting/naive B cells \[[@B44]\]. Gass *et al*., (2002) exploited the unfolded protein response (UPR) in B lymphocytes and found it to be induced during B cell transition to antibody secreting plasma cells, thus suggesting a link between upregulation of this protein with immunoglobulin synthesis \[[@B45]\]. Loss of BiP function in B cells has been associated with inability to secrete functional antibodies, which may ultimately affect opsonization of invading pathogens \[[@B46]\].

In particular, *M. tuberculosis* infection exerts stress on immune cells through secretion of ESAT-6, which affects homeostasis of calcium ions and increases unfolded protein burden in cells due to a metabolic shift. However, it has been implied that extended ER stress can lead to activation of apoptotic pathways in immune cells resulting in skewed immunological responses \[[@B8],[@B47]\]. As illustrated in [Figure 4](#F0004){ref-type="fig"}, ER stress activates and upregulates expression of BiP and other ER chaperones to mitigate the conditions affecting cells \[[@B42]\]. These chaperone proteins bind unfolded and partially folded proteins and direct them for proper folding in the ribosomes \[[@B48]\]. They also act as coactivators of three ER membrane signal transducers; PERK, IRE1 and ATF6 ([Figure 4](#F0004){ref-type="fig"}), which in turn phosphorylate transcription factors and cytosol kinase involved in translation termination and cytokine synthesis. These mechanisms either promote cell apoptosis or cell survival.

![**Unfolded protein response mediated by binding immunoglobulin protein.**\
Activation of the ER membrane transducers leads to a cascade of kinase phosphorylation that either favors apoptosis through upregulation of CHOP or JNK activation. Similarly, cell survival can be favored by blocking translation and degrading synthesized mRNA.\
ER: Endoplasmic reticulum; UPR: Unfolded protein response.](fsoa-05-379-g4){#F0004}

Even though BiP is natively an intracellular protein, it has been reported to be capable of translocating to and being expressed on cell membranes attached to peripheral proteins including both transmembrane and external proteins such as glycosylphosphotidylinositol. Similarly, it can be secreted into the extracellular environment \[[@B49]\] where it acts as an autoantigen and exerts effects on immune cells through binding with surface receptors \[[@B50],[@B51]\]. Over the last few years, its effect has been exploited in different immune cells including macrophages, dendritic cells, monocytes, T cells and B cells. The BiP facilitates differentiation of mature dendritic cells to express an anti-inflammatory phenotype through upregulation of indoleamine-2,3-dioxygenase (IDO) \[[@B30]\] and also stimulates myeloid cells to express an anti-inflammatory phenotype mostly observed in immature dendritic cells \[[@B52]\]. In a study by Corrigall *et al*., (2004) BiP was shown to act on human peripheral blood mononuclear cells to induce anti-inflammatory responses through upregulation of IL-10 \[[@B50]\]. It also affects the expression of CD86 and HLA-DR surface expression on monocytes, which causes these APCs to be unable to activate T cells. The BiP also alters the ability of memory T cells to recall antigens and initiate secondary responses \[[@B31]\].

Immunological effects caused by BiP have ultimately resulted in study in areas relating to cancer, transplantation and autoimmune studies \[[@B31],[@B53]\]. Contradicting results, however, were observed in *Giardia lamblia* infection in murine samples where recombinant BiP extracted from *G lamblia* (rGlBiP) demonstrated a pro-inflammatory response through upregulation of CD80, CD86 and MHC II on mature dendritic cells, leading to increased production of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α \[[@B54]\]. Another study \[[@B41]\] showed that T cell surface BiP expression can be upregulated by pro-inflammatories such as TNF-α and IL-1β. Additionally, this upregulation was associated with increased proliferation of synoviocyte cells and progressive pathogenesis of RA in synoviocytes. This suggested that T cell surface BiP can modulate pro-inflammatory responses in synoviocytes Interestingly, transfection of the BiP gene into murine and human PBMC samples using a viral vector has been evaluated as having the same anti-inflammatory effects as stimulating arthritis inflammation with synthesised proteins in collagen \[[@B55]\]. Supporting evidence of extracellular BiP binding to immune cells was shown in a study by Tang *et al*., (2016) where BiP induced the development of regulatory B cells in murine samples and worked in synergy with CD40 to suppress proliferation of T cells \[[@B29]\].

Binding of extracellular BiP with immune cells {#S0004}
----------------------------------------------

The BiP is a member of heat-shock proteins (Hsp70) that has been reported to have immune modulatory functions. Unlike other members of the Hsp70s, which are implicated in induction of pro-inflammatory immune responses, BiP is reported to mostly facilitate anti-inflammatory responses. As a result, this chaperone has been studied in the induction of functional changes in immune cells \[[@B50],[@B56],[@B57]\]. Secreted BiP binds to cell receptors as an autoantigen and causes functional changes. However, pathways involved in these processes are not fully elucidated ([Figure 2](#F0002){ref-type="fig"}), although it has been stated that most of the Hsp70 proteins are secreted through passive secretion. Studies on RA and cancer that have identified extracellular BiP observed that it is secreted without its anchor, a four amino acid sequence KDEL, thus suggesting that it is not available as a result of membrane rupture or cell death \[[@B50]\]. In particular, a study in murine collagen induced arthritis revealed an IL-4 dependent effect of BiP on T cell responses that leads to secretion of anticollagen specific cytokines including IL-5 and IL-10 \[[@B53]\]. Even though BiP upregulation is beneficial to immune responses as it activates signal transducers that mediate cytokine and antibody gene expression; similarly, its downregulation has been associated with benefits in cancer suppression that could be a target of choice in studies such as for B cell lymphoma.

Targeting this chaperone could be a promising approach that will aid in the development of new therapeutic procedures that will better control inflammation during diseases \[[@B30],[@B52]\]. Less data have been generated on binding of extracellular BiP onto immune cells since previous studies have focused mainly on monitoring the cytokine profile in immune cell samples in the presence of BiP rather than assessing binding receptors or pathways involved during internalization. However, it has been suggested in a study by Becker *et al*., (2002) that free Hsp70 proteins binds immune cells, such as B cells, through CD40 in an ATPase-dependent manner \[[@B58]\]. Even though this pathway has not been fully studied, BiP binding with immune cells such as B cells was also shown by Tang *et al*., (2016) using fluorescently labeled BiP in murine model \[[@B29]\]. Binding and internalization of this chaperone protein on B cell samples induced upregulation of three populations of Bregs with distinct phenotypes (IL-10^hi^, PDL-1 and FasL), thus highlighting different regulatory mechanisms \[[@B29]\].

Regulatory function of mature/active regulatory B cells {#S0005}
-------------------------------------------------------

Initial studies on Bregs implied that these cells were only modulating immune responses until regulatory T cells were mature enough to take over the function. However, further studies elaborated on immune functions played by these cells using murine models and have shown that Bregs exert their function mostly through IL-10 \[[@B33],[@B35]\]. Similar results have been obtained in human models, where both cytokines and cell surface receptors are implicated in the regulatory roles of these cells \[[@B59]\]. Even though their development depends on various factors, including the type of stimulant and the presence of micronutrients to drive immunometabolism, these cells have been shown to inhibit proliferation and function of macrophages, T helper 1 (Th1), and T helper 17 (Th17) cells, while leaving T helper 2 (Th2) function unaffected \[[@B22]\]. In various studies this was confirmed by a decrease in secreted levels of cytokines such as IFN-γ and IL-17, while IL-4 levels appear to not be affected by presence of regulatory B cells \[[@B22],[@B23]\]. Breg importance lies in their maintaining immune balance after inflammatory responses in order to prevent autoimmune diseases progression by suppressing persisting T cell responses \[[@B60]\]. Cell-to-cell immunomodulatory function of Bregs occurs through expression of ligands that target and bind to specific surface receptors expressed by other immune cells and this binding further enhances apoptotic pathways. Such immunomodulatory ligands include PDL-1, which targets PD-1 membrane protein on activated T cells and monocytes; FasL, which stimulates apoptosis of infected macrophages during chronic infections such as TB \[[@B25],[@B61],[@B62]\]; and GITR, which has been shown to be associated with negatively modulating proliferation of regulatory T cells during RA through binding to the GITRligand expressed by these cells \[[@B12]\].

Immune responses driven by low or high frequencies of Bregs {#S0006}
-----------------------------------------------------------

In allograft and autoimmune diseases, high frequency of Bregs is associated with preventing progression into aggressive stages of inflammation. The functions carried by these cell subsets are highly similar to Tregs; however, these functions are believed to be alternating during inflammation in a sense that Bregs are mostly active during the onset of inflammation whereas Tregs come to action toward the end of inflammation. This notion has been supported in a variety of studies where Bregs were isolated in higher frequencies in healthy individuals but eventually deplete as inflammatory responses progresses \[[@B22],[@B35]\]. The same 'depletion-reappearing' trait of these cells has been observed in studies focusing on different inflammatory responses using both murine and human models \[[@B8],[@B22],[@B25],[@B35]\]. Recently, it has been observed in human samples studying B cell immune responses during *M. tuberculosis* infection. This was believed to play a part in disease progression as their numbers vanished during active TB disease but, upon treatment, Bregs reappeared to a frequency equivalent to healthy individuals \[[@B62]\]. Expression of regulatory traits in B cells has been described in varying frequencies depending on B cell development stage, location and type of inflammation. Highlighted in [Table 1](#T1){ref-type="table"} are the recently reported frequencies of different Breg populations in uninfected or healthy individuals and these range from 0.1% to as high as 12% of the total described B cell population. However, *in vitro* these frequency percentages could be stimulated to increase using different stimulants among which are LPS, TLR-9 agonist and BGC \[[@B24],[@B38],[@B59]\].

###### **Defined regulatory B cell population frequencies in healthy human individuals expressing different surface markers and exhibiting diverse regulatory mechanisms.**

  ------------------------------------------------------------------------------------------------------------
  **Phenotype**            **Species**      **Percentage (%)**   **Mechanism of suppression**   **\[Ref.\]**
  ------------------------ ---------------- -------------------- ------------------------------ --------------
  CD24^hi^CD27^+^          Human, PBMC      0.6                  IL-10                          \[[@B63]\]

                                                                                                

  CD24^+^CD38^+^\          Human            3.92\                IL-10                          \[[@B59]\]
  CD24^hi^CD38^-^\                          3.71\                                               
  CD24^hi^CD38^int^\                        12.6                                                
  CD24^hi^CD38^hi^                                                                              

                                                                                                

  CD5^+^CD1d^+^IL10^+^     Human, PBMC      0.24 ± 0.05          IL1-0                          \[[@B64]\]

                                                                                                

  CD19^+^IgM^+^CD38^+^\    Human, PBMC      0.1--1.6             FasL                           \[[@B25]\]
  -- FasL^+^\                                                                                   
  -- PD1^+^                                                                                     

                                                                                                

  CD19^+^IgM^-^CD38^+^\    Human, PBMC      0.1--1.5             FasL                           \[[@B25]\]
  -- FasL^+^\                                                                                   
  -- PD1^+^                                                                                     

                                                                                                

  CD19^+^PDL1^hi^\         Human, spleen\   5.2\                 PDL1\                          \[[@B18]\]\
  CD19^+^CD138^+^CD27^+^   Human, PBMC      2.99                 Il-10                          \[[@B24]\]
  ------------------------------------------------------------------------------------------------------------

Presence of Bregs and high secretion levels of IL-10 from these cells modulates differentiation of certain T cell subsets expressing CD4^+^CD25^-^ T cells to Tregs expressing FoxP3, which further mediate regulatory functions during inflammation \[[@B22]\]. *In vitro* work has shown that high levels of IL-10 are linked to impaired secretion and activity of certain pro-inflammatory cytokines such as TNF-α, IL-12, IL1-β and IL-17 \[[@B22],[@B23],[@B65],[@B66]\]; these are required during early inflammation to initiate and activate adaptive responses by recruiting T- and B cells. However, in the context of *M. tuberculosis* infection, engagement of adaptive responses has been speculated to favor TB disease progression through the formation of granulomas that later become replication sites for the intracellular pathogen, leading to more cells being infected within the structure as bacterial numbers grow and infected cells rupture through cellular necrosis and pyroptosis.

Regulatory B cells as agents in therapeutic interventions {#S0007}
---------------------------------------------------------

Inflammatory responses directed to intracellular pathogens such as *M. tuberculosis* face challenges in directly eliminating the pathogen from inside the cell \[[@B67]\]. This phenomenon results as pathogens such as *M. tuberculosis* have evolved a way to suppress destruction by proteolytic enzymes inside the phagosomes \[[@B68],[@B69]\]; additionally, antibodies and cytokines secreted toward this pathogen cannot penetrate cellular membranes to reach it, thus resulting in established infection and disease progression \[[@B70]\]. Even though formation of granulomatous structures during TB helps in containing the pathogen and preventing early spread \[[@B71]\], the pathogen may multiply to higher numbers and progress to active disease \[[@B7],[@B71]\]. Immune cell activity within the granuloma structure and upregulation of necrotic cytokines and perforins lead to destruction of infected cells by necrosis, which in turn leads to the release of more pathogens to infect other cells \[[@B72],[@B73]\]. Comparatively, Bregs have been suggested to induce apoptosis of infected cells by affecting cellular metabolism -- which in turn affects homeostasis of calcium -- reactive oxygen species and nitric oxide, thus affecting survival of the intracellular pathogen \[[@B72],[@B74]\]. This prevents presentation of antigens and activation of effector T cells, thus limiting activation of adaptive immune responses \[[@B31],[@B75]\]. Stimulating development or maintaining frequency of these regulatory cells can present more benefits in host-directed immunotherapies and control of intracellular pathogens like *M. tuberculosis*.

Conclusion & future perspective {#S0008}
===============================

Regulatory characteristic induction by BiP in B cells {#S0009}
-----------------------------------------------------

Little data are currently available on the induction of human regulatory B cells using BiP, indicating that more work still needs to be done to understand the pathways involved in the development of these cell types. Previous reports have shown that BiP has anti-inflammatory properties through induction of regulatory cells and this has been evaluated in different inflammatory studies with successful results \[[@B31],[@B57]\]. Apart from inducing immune regulatory functions, its activity in immunoglobulin folding results in better antibody secretion which in turn facilitates better control of infectious pathogens \[[@B76]\]. Its biological nature gives it an additional advantage by limiting nonspecific inflammatory responses that may end up causing immuno-pathogenesis. The availability of this molecule in extracellular circulation and its autoantigen properties facilitate secretion of autoantibodies against it. This also shows an additional advantage since immune cells will efficiently opsonize and internalize it, resulting in shorter time required for development of regulatory traits. Induction of these traits in B cells using BiP in a murine model study and its implication in inducing regulatory traits in T cells in human model studies have paved the way for, and indicated a high possibility for, Breg induction by this antigen in human settings \[[@B29]\]. More studies must be conducted in the context of *M. tuberculosis* infection and BiP behavior.

###### Executive summary

-   Antigen presenting cells (APCs) opsonize and internalize invading *M. tuberculosis* particles; however, this pathogen is able to reside and multiply within these cells leading to granulomatous structure formation.

-   B cells can differentiate into a variety of subsets, which includes effector B cells, plasma, memory and regulatory cells.

-   During chronic diseases, including tuberculosis, B cells are shown to be dysfunctional in blood circulation and *M. tuberculosis* infection takes advantage of this immune imbalance.

-   Regulatory functions mediated by B cells was described during experimental autoimmune encephalomyelitis and shown to resolve disease progression.

-   Apart from IL-10 secretion, these cells express surface markers such as sFas-L, PD-L1 and FoxP3.

-   There are four groups of regulatory B cells which are grouped based on their mode of action; IL-10 producing B cells, TGF-β secreting B cells, IL-35 secreting B cells and FoxP3 expressing B cells.

-   Regulatory B cells are known to be inducible by various factors such as BiP, BCG, LPS, infectious agents and TLR-9a.

-   Binding immunoglobulin protein (BiP) resides in the endoplasmic reticulum and facilitate proper protein folding; its activity is induced during cellular stress conditions posed onto cells by accumulation of unfolded proteins among others.

-   Its activation results from the unfolded protein response pathway, which is thought to be a survival mechanism that T cells use during such conditions; however, prolonged cell stress can lead to induction of apoptotic pathways.

-   Unfolded protein response is also mediated by three endoplasmic reticulum membrane-bound transducers (PERK, IRE1 and ATF6) that act as coactivators during this pathway and their activity determines between cell survival or cell apoptosis.

-   The BiP can escape intracellular environment and act as autoantigen in the extracellular matrix and its effect has been observed in various cell types including macrophages, dendritic cells, monocytes T and B cells.

-   Its presence in the extracellular matrix has been shown to induce regulatory traits on immune cells and further resolve inflammation.

-   Regulatory B cells are known to inhibit proliferation and functions mediated by macrophages, T helper 1 and T helper 17 cells, while leaving T helper 2 function unaffected.

-   High frequencies of regulatory B cells are associated with preventing disease progression.

-   Regulatory B cells disappearance during chronic diseases is thought to play part in disease progression particularly during TB.

-   Ability of BiP to modulate immunological responses and drive anti-inflammatory properties has set a promising research platform in chronic inflammation.

-   Its secretion is suggested to be passive in conjunction with newly synthesized proteins as it was isolated in the extracellular matrix during rheumatoid arthritis without its membrane anchor sequence.
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